{"id":"W2979367976","doi":"10.1182/blood.v124.21.3450.3450","title":"Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ixazomib; Medicine; Tolerability; Internal medicine; AL amyloidosis; Adverse effect; Population; Progression-free survival; Oncology; Proteasome inhibitor; Gastroenterology; Surgery; Multiple myeloma; Carfilzomib; Overall survival; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002134145,0.0007421768,0.00111198,0.0002408267,0.0005060495,0.0009517786,0.0004084909,0.0006925658,0.001493345],"category_scores_gemma":[0.001350934,0.0003084601,0.001054958,0.0002767351,0.0005997016,0.0006407904,0.0004884483,0.002057944,0.0005041495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006909174,"about_ca_system_score_gemma":0.0006344035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004588419,"about_ca_topic_score_gemma":0.0007517522,"domain_scores_codex":[0.9993973,0.0002614885,0.00003333594,0.0001269756,0.00008047478,0.0001005348],"domain_scores_gemma":[0.9987983,0.0001710642,0.0003343432,0.0001205249,0.0000793806,0.0004964232],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6431174,0.05260656,0.1259829,0.0005931541,0.003706347,0.001082284,0.0006834447,0.004373807,0.04865485,0.000183699,0.004128436,0.114887],"study_design_scores_gemma":[0.06528343,0.6600479,0.257804,0.00004378309,0.002413797,0.001138668,0.0001717984,0.002356181,0.006536704,0.0003023834,0.003843322,0.00005802402],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976222,0.0008126919,0.0001968647,0.00009594439,0.0000263801,0.0002290771,0.0004627436,0.00001476184,0.0005393461],"genre_scores_gemma":[0.9971308,0.0003033165,0.0002371796,0.0002181155,0.00006073317,0.0002286795,0.001176311,0.000005405973,0.0006394883],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002134145,"threshold_uncertainty_score":0.01128656,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01837576400258882,"score_gpt":0.2812643872802549,"score_spread":0.2628886232776661,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}